497 related articles for article (PubMed ID: 23274666)
21. Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
Chukkapalli V; Berger KL; Kelly SM; Thomas M; Deiters A; Randall G
Virology; 2015 Feb; 476():168-179. PubMed ID: 25546252
[TBL] [Abstract][Full Text] [Related]
22.
Asante-Appiah E; Liu R; Curry S; McMonagle P; Agrawal S; Carr D; Rokosz L; Lahser F; Bystol K; Chase R; Black S; Ferrari E; Ingravallo P; Tong L; Yu W; Kozlowski J
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150466
[TBL] [Abstract][Full Text] [Related]
23. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
Wang C; Jia L; O'Boyle DR; Sun JH; Rigat K; Valera L; Nower P; Huang X; Kienzle B; Roberts S; Gao M; Fridell RA
Antimicrob Agents Chemother; 2014 Sep; 58(9):5155-63. PubMed ID: 24936600
[TBL] [Abstract][Full Text] [Related]
24. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
Lenz O; Verbinnen T; Lin TI; Vijgen L; Cummings MD; Lindberg J; Berke JM; Dehertogh P; Fransen E; Scholliers A; Vermeiren K; Ivens T; Raboisson P; Edlund M; Storm S; Vrang L; de Kock H; Fanning GC; Simmen KA
Antimicrob Agents Chemother; 2010 May; 54(5):1878-87. PubMed ID: 20176898
[TBL] [Abstract][Full Text] [Related]
25. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.
Wang C; Sun JH; O'Boyle DR; Nower P; Valera L; Roberts S; Fridell RA; Gao M
Antimicrob Agents Chemother; 2013 May; 57(5):2054-65. PubMed ID: 23403428
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).
McPhee F; Sheaffer AK; Friborg J; Hernandez D; Falk P; Zhai G; Levine S; Chaniewski S; Yu F; Barry D; Chen C; Lee MS; Mosure K; Sun LQ; Sinz M; Meanwell NA; Colonno RJ; Knipe J; Scola P
Antimicrob Agents Chemother; 2012 Oct; 56(10):5387-96. PubMed ID: 22869577
[TBL] [Abstract][Full Text] [Related]
28. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
Yang H; Robinson M; Corsa AC; Peng B; Cheng G; Tian Y; Wang Y; Pakdaman R; Shen M; Qi X; Mo H; Tay C; Krawczyk S; Sheng XC; Kim CU; Yang C; Delaney WE
Antimicrob Agents Chemother; 2014; 58(2):647-53. PubMed ID: 23939899
[TBL] [Abstract][Full Text] [Related]
29. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
Gao M; Nettles RE; Belema M; Snyder LB; Nguyen VN; Fridell RA; Serrano-Wu MH; Langley DR; Sun JH; O'Boyle DR; Lemm JA; Wang C; Knipe JO; Chien C; Colonno RJ; Grasela DM; Meanwell NA; Hamann LG
Nature; 2010 May; 465(7294):96-100. PubMed ID: 20410884
[TBL] [Abstract][Full Text] [Related]
30. IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System.
Aboulnasr F; Hazari S; Nayak S; Chandra PK; Panigrahi R; Ferraris P; Chava S; Kurt R; Song K; Dash A; Balart LA; Garry RF; Wu T; Dash S
PLoS One; 2015; 10(12):e0141655. PubMed ID: 26657215
[TBL] [Abstract][Full Text] [Related]
31. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
Hernandez D; Yu F; Huang X; Kirov S; Pant S; McPhee F
Adv Ther; 2016 Jul; 33(7):1169-79. PubMed ID: 27287851
[TBL] [Abstract][Full Text] [Related]
32. The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
Lahser FC; Bystol K; Curry S; McMonagle P; Xia E; Ingravallo P; Chase R; Liu R; Black T; Hazuda D; Howe AY; Asante-Appiah E
Antimicrob Agents Chemother; 2016 May; 60(5):2954-64. PubMed ID: 26926625
[TBL] [Abstract][Full Text] [Related]
33. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
Jacobson I; Zeuzem S; Flisiak R; Knysz B; Lueth S; Zarebska-Michaluk D; Janczewska E; Ferenci P; Diago M; Zignego AL; Safadi R; Baruch Y; Abdurakhmanov D; Shafran S; Thabut D; Bruck R; Gadano A; Thompson AJ; Kopit J; McPhee F; Michener T; Hughes EA; Yin PD; Noviello S
World J Gastroenterol; 2016 Mar; 22(12):3418-31. PubMed ID: 27022224
[TBL] [Abstract][Full Text] [Related]
34. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.
Asante-Appiah E; Curry S; McMonagle P; Ingravallo P; Chase R; Nickle D; Qiu P; Howe A; Lahser FC
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416549
[TBL] [Abstract][Full Text] [Related]
35. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.
Malcolm BA; Liu R; Lahser F; Agrawal S; Belanger B; Butkiewicz N; Chase R; Gheyas F; Hart A; Hesk D; Ingravallo P; Jiang C; Kong R; Lu J; Pichardo J; Prongay A; Skelton A; Tong X; Venkatraman S; Xia E; Girijavallabhan V; Njoroge FG
Antimicrob Agents Chemother; 2006 Mar; 50(3):1013-20. PubMed ID: 16495264
[TBL] [Abstract][Full Text] [Related]
36. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.
Wang C; Huang H; Valera L; Sun JH; O'Boyle DR; Nower PT; Jia L; Qiu D; Huang X; Altaf A; Gao M; Fridell RA
Antimicrob Agents Chemother; 2012 Mar; 56(3):1350-8. PubMed ID: 22214777
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus.
Hamana A; Takahashi Y; Uchida T; Nishikawa M; Imamura M; Chayama K; Takakura Y
Antiviral Res; 2017 Oct; 146():130-138. PubMed ID: 28864074
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
Wang C; Jia L; Huang H; Qiu D; Valera L; Huang X; Sun JH; Nower PT; O'Boyle DR; Gao M; Fridell RA
Antimicrob Agents Chemother; 2012 Mar; 56(3):1588-90. PubMed ID: 22203595
[TBL] [Abstract][Full Text] [Related]
40. Multi-scale model for hepatitis C viral load kinetics under treatment with direct acting antivirals.
Clausznitzer D; Harnisch J; Kaderali L
Virus Res; 2016 Jun; 218():96-101. PubMed ID: 26409026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
